|
| Status |
Public on Jun 09, 2023 |
| Title |
RAGE Inhibitor TTP488 (Azeliragon) Reduces Metastasis in Triple-Negative Breast Cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We tested the preclinical efficacy of two small molecule RAGE inhibitors (TTP488 (Azeliragon) and FPS-ZM1) against TNBC metastasis in the orthotopic xenograft MDA-MB-231/4175 - NSG model. Both TTP488 and FPS-ZM1 impaired TNBC metastasis in this lung metastatic breast cancer model, with TTP488 affecting metastasis to a greater degree than FPS-ZM1. Transcriptomic analysis of the primary tumors revealed that TTP488 and FPS-ZM1 displayed high concordance in gene expression changes affecting metastatic pathways.
|
| |
|
| Overall design |
Comparison of gene expression changes in RAGE inhibitor treated primary tumor tissues and vehicle (DMSO) treated tumors.
|
| Web link |
https://pubmed.ncbi.nlm.nih.gov/37443146/
|
| |
|
| Contributor(s) |
Hudson B, McIntosh A, Magna M |
| Citation(s) |
37443146 |
| |
| Submission date |
Sep 27, 2022 |
| Last update date |
Oct 17, 2023 |
| Contact name |
Barry I Hudson |
| E-mail(s) |
barry.hudson@georgetown.edu
|
| Organization name |
Georgetown University
|
| Department |
Oncology
|
| Lab |
Hudson lab
|
| Street address |
3970 Reservoir Road,
|
| City |
NW Washington |
| State/province |
District of Columbia |
| ZIP/Postal code |
20007 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (6)
|
|
| Relations |
| BioProject |
PRJNA884681 |
Less...
More...